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Abstract Glucose deprivation, hypoxia and acidosis are char-
acteristic features of the central core of most solid tumours.
Myofibroblasts are stromal cells present in many such solid
tumours, including those of the colon, and are known to be
involved in all stages of tumour progression. HMGB1 is a
nuclear protein with an important role in nucleosome
stabilisation and gene transcription; it is also released from
immune cells and is involved in the inflammatory process.
We report that the microenvironmental condition of glucose
deprivation is responsible for the active release of HMGB1
from various types of cancer cell lines (HT-29, MCF-7 and
A549) under normoxic conditions. Recombinant HMGB1
(10 ng/ml) triggered proliferation in myofibroblast cells via
activation of PI3K and MEK1/2. Conditioned medium col-
lected from glucose-deprived HT-29 colon cancer cells stim-
ulated the migration and invasion of colonic myofibroblasts,
and these processes were significantly inhibited by
immunoneutralising antibodies to HMGB1, RAGE and
TLR4, together with specific inhibitors of PI3K and MEK1/2.
Our data suggest that HMGB1 released from cancer cells under
glucose deprivation is involved in stimulating colonic
myofibroblast migration and invasion and that this occurs
through the activation of RAGE and TLR4, resulting in the
activation of the MAPK and PI3K signalling pathways. Thus,
HMGB1 might be released by cancer cells in areas of low
glucose in solid tumours with the resulting activation of
myofibroblasts and is a potential therapeutic target to inhibit
solid tumour growth.
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Introduction
A dynamic stroma that changes with alterations occurring in
the epithelium is fundamental for the maintenance of epithe-
lial tissue. In cancer, these changes maintain an environment
that supports proliferation and metastasis (Mareel and Leroy
2003; Tang et al. 2013). Under normal conditions, fibroblasts
exhibit little extracellular matrix (ECM) or cell matrix con-
tacts. However, in the event of tissue injury or inflammation,
fibroblasts transdifferentiate into myofibroblasts, migrate to
damaged tissue and help in the formation of the ECM by
producing collagen, fibronectin, tenascin and versican
(Vaughan et al. 2000; Hinz et al. 2007). Myofibroblasts are
spindle-shaped cells transiently found in early to mid-phase
wound tissue (Werner et al. 2007). In addition, they are pres-
ent in abundance in most solid tumours (Downs-Kelly et al.
2013; Nagarajan et al. 2013; Yeung et al. 2013; Yoshida et al.
2013). Myofibroblasts have also been shown to promote in-
vasiveness in breast carcinoma and pancreatic carcinoma
(Dabiri et al. 2013; Hu et al. 2008; Mareel et al. 2009). In
the tumour microenvironment, cancer cells stimulate stromal
cells, such as myofibroblasts, to secrete growth factors includ-
ing insulin-like growth factor-2 (IGF-2) and hepatocyte
growth factor (HGF; Duckworth et al. 2013). Moreover, these
myofibroblasts produce proteases, including various matrix
metalloproteinases, which can cleave matrix components
(Chien et al. 2013; Guan et al. 2015; Holmberg et al.
2013; Luca et al. 1997). Whereas myofibroblasts appear
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to play important roles within the tumour microenviron-
ment, the factors that regulate them remain largely un-
known. In view of the evidence that the myofibroblast
population increases at various progressive stages of in-
vasive carcinomas (De Wever et al. 2008), cancer cells
can be hypothesised to release factors that influence
myofibroblast proliferation, migration and invasion.
High mobility group box1 (HMGB1) protein is a non-
histone protein involved in the stabilisation of nucleosomes
and the bending of DNA to facilitate gene transcription
(Lange et al. 2008; G. Li et al. 2013). It is expressed in all
vertebrate cells and in yeast, plants and bacteria (Bustin et al.
1990). It does not possess a signal sequence and therefore
does not transverse the endoplasmic reticulum. However, it
is released actively by various cells, such as macrophages
(Gardella et al. 2002), pituicytes and erythroleukemia cells,
and mediates innate and adaptive inflammatory responses to
injury and inflammation (Tang et al. 2007). Although
HMGB1 is a nuclear protein, it has also been reported to take
part in the immune system when passively released by necrot-
ic cells or actively secreted by inflammatory cells such as
dendritic cells in the extracellular milieu (Dumitriu et al.
2005; Tang et al. 2007). Recently, the effect of HMGB1 on
fibroblasts and keratinocytes has been studied and HMGB1
appears to stimulate keratinocyte scratch wound healing in
vitro. In addition, HMGB1 has been shown to induce prolif-
eration and migration of keratinocytes via the extracellular
signal-regulated kinase (ERK) pathway (Hamada et al. 2008;
Ranzato et al. 2009; Yang et al. 2007).
HMGB1 has been reported to modulate this cytokine-like
activity by interacting with multiple receptors including the
receptor for advanced glycation end products (RAGE;
Kokkola et al. 2005) and the toll-like receptor 2/4 (TLR2
and TLR4; Curtin et al. 2009; Kim et al. 2013). RAGE be-
longs to the immunoglobulin superfamily and is expressed in
many cells including monocytes, macrophages, smooth mus-
cle cells and endothelial cells. Fibroblasts have been shown to
express RAGE and the activation of RAGE has been correlat-
ed with the proliferation and migration of fibroblasts in the
tumour microenvironment (Liu et al. 2010; Rojas et al. 2010).
In this study, we have hypothesised that HMGB1 is
released from cancer cells under tumour microenviron-
mental stress conditions and that this protein promotes
proliferation, migration and invasion of myofibroblasts.
Our work shows that the microenvironmental condition
of glucose deprivation is responsible for the active re-
lease of HMGB1 from HT-29 colon cancer cells and
other cancer cell lines. In addition, we demonstrate that
HMGB1 stimulates myofibroblast proliferation, migration
and invasion through a mechanism that involves the activation
of RAGE and TLR4 receptors and the mitogen-activated pro-
tein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)
cell signalling pathways.
Materials and methods
Cells and drugs Human colonic myofibroblast cells
CCD18COCo (ATCC CRL1459), colon adenocarcinoma cells
HT-29 (ATCC HTB-38), lung cancer cells A549 (ATCC
CCL185) and breast cancer cells MCF7 (ATCC HTB22) were
obtained from ATCC (LGC Standards, Middlesex, UK) and
bladder cancer cells EJ138 were obtained from ECACC
(Public Health England, Salisbury, UK). All cells were used
within 6 months of resuscitation and were authenticated by the
ATCC or ECACC by using standard protocols prior to purchase.
Cells were cultured in minimum essential medium from Sigma-
Aldrich (Dorset, UK) supplemented with 10 % fetal bovine se-
rum (Labtech International, East Sussex, UK). Human colonic
myofibroblast cells were used up to passage 10. The human
recombinant HMGB1, anti-HMGB1 primary antibody, anti-
RAGE primary antibody and anti-TLR4 primary antibody were
purchased from R&D Systems (Oxford, UK). MEK1/2 inhibitor
(U0126) and PI3K inhibitor (LY294002) were purchased from
Cell Signaling Technology (Massachusetts, USA). Protease and
phosphatase cocktail set inhibitors were purchased from
Calbiochem (Nottingham,UK). All other reagents were obtained
from Fisher Scientific (Leicestershire, UK), BioRad Laboratories
(Hertfordshire, UK) or Sigma-Aldrich.
SDS-polyacrylamide gel electrophoresis and western blot
Conditioned serum-free medium (without glucose or without
glutamine) was collected from HT-29, MCF-7, EJ138 and
A549 cells after 48 h of conditioning. In addition, cell lysates
for analysis were prepared from cells by using RIPA lysis
buffer (Life Technologies, Paisley, UK) containing protease
inhibitor cocktail set III (10 μl/ml) and phosphatase inhibitor
cocktail set II (10 μl/ml).
The CCD18Co cells were treated with either fresh serum-
and glucose-free medium or fresh serum-free glucose-
containing medium for 24 h before analysis. In addition, the
CCD18Co cells were treated (22 h) with serum and glucose-
freemedium or serum-free glucose-containingmedium that had
previously been conditioned on HT-29 cells for 48 h. Medium
samples and cell lysates were resolved by using SDS-
polyacrylamide (9 %) gel electrophoresis and transferred to
high-bond nitrocellulose membrane (GE Healthcare,
Buckinghamshire, UK). The blots were incubated overnight
at 4 °C with primary antibodies to HMGB1, RAGE or TLR4,
followed by a 1-h incubation at room temperature with the
appropriate horseradish-peroxidise-conjugated secondary anti-
body. The blots were then incubated with SuperSignal West
Pico Chemiluminescent Substrate with enhanced chemilumi-
nescence (ECL; Thermo Scientific, Northumberland, UK), de-
veloped and fixed in the dark room.
Proliferation assays CCD18Co cells were cultured in
24-well plates (5×104/well) and serum-starved for 24 h prior
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to HMGB1 treatment. They were then treated with recombi-
nant HMGB1 at a range of doses (0.01 to 100 ng/ml) and
incubated at 37 °C, 95 % humidity and 5 % CO2 for either
48 h or 96 h. After treatment with HMGB1, the proliferative
effect of recombinant HMGB1 on CCD18Co cells was
assessed by using Neutral Red Uptake (NRU) or MTT (3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) as-
says according to standard protocols.
The effect of MEK1/2 inhibitor (U0126) or PI3K inhibitor
(LY294002) was also measured by using the MTT assay. The
CCD18Co cells (5×104/well) were cultured in 24-well plates in
serum-free medium for 24 h followed by treatment with U0126
(50 μM) and LY294002 (10 μM) in serum-free medium for
48 h. In addition, the inhibitory effects of the MEK1/2 inhibitor
(U0126) and PI3K inhibitor (LY294002) on the recombinant-
HMGB1-induced proliferation of CCD18Co cells were mea-
sured by using the MTT assay. The CCD18Co cells (5×104/
well) were cultured in 24-well plates in serum-free medium for
24 h prior to treatment with HMGB1 (10 ng/ml) with U0126
(50 μM) or LY294002 (10 μM) in serum-free medium for 48 h
before assessment by the MTT assay.
Migration assays The migratory effect of CCD18Co cells in
response to medium previously conditioned on HT-29 cells
for 20 h was studied by using 8-μm-pore Boyden chamber
inserts in a 24-well plate system (BD Bioscience, California,
USA). CCD18Co cells (6×104/well) were seeded onto the
inserts in serum-free medium. Conditioned medium or condi-
tioned medium with the addition of a variety of inhibitors and
antibodies (MEK1/2 and PI3K inhibitors and anti-HMGB1,
anti-RAGE and anti-TLR4 antibodies) was added to the lower
chamber and the plate was incubated for 20 h at 37 °C, 95 %
humidity and 5 % CO2 to allow the cells to migrate. CCD18Co
cell migration across the 8-μm-pore membrane was detected by
using REASTAIN Quick-Diff stain (Dade Behring, Delaware,
USA). The total cells in five microscopic fields of vision (× 20)
per well were photographed and counted and the mean cell
count of 6 wells per experiment was determined.
Invasion assays Invasion assays with CCD18Co cells were
performed by using 8-μm-pore matrigel matrix Biocoat in-
serts according to the manufacturer’s instructions (Becton
Dickinson, Oxford, UK). The CCD18Co cell suspension
was prepared in serum-free medium (6×104/ml). The
CCD18Co cell suspension was seeded onto the matrigel in-
serts (0.5 ml per insert) in a 24-well plate supplied by the
manufacturer. HT-29-cell-conditioned medium was used as a
chemoattractant and was added into the lower chamber. The
plate was incubated for 22 h at 37 °C, 95 % humidity and 5 %
CO2. In addition to the standard invasion assay, the medium in
the CCD18Co cell suspension and conditioned medium used
at the bottom chamber were supplemented with a variety of
inhibitors and neutralising antibodies. The CCD18Co cell
invasion, in response to the conditioned medium with and
without MEK1/2 and PI3K inhibitors or anti-HMGB1, anti-
RAGE and anti-TLR4 antibodies, was determined by their
inclusion in the lower chamber of the 24-well plate. Cells
invading through the matrigel matrix membrane were
detected on the lower surface by using the REASTAIN
Quick-Diff staining method and were counted as
described above.
Results
HMGB1 triggers proliferation in myofibroblasts via
MAPK and PI3K signalling pathways To determine the pro-
liferative effect of HMGB1, myofibroblasts were treated with
a range of concentrations (1–100 ng/ml) of recombinant
HMGB1 for 96 h. We observed that a wide range of concen-
trations stimulated statistically significant myofibroblast pro-
liferation (1–50 ng/ml) compared with the control (Fig. 1). A
statistically significant increase in proliferation of
myofibroblasts was also stimulated by HMGB1 (10 ng/ml)
at an earlier time point of 48 h (Fig. 2).
The MAPK and PI3K signalling pathways have previously
been reported to be involved in colonic myofibroblast prolif-
eration (Hemers et al. 2005). Since 10 ng/ml HMGB1 signif-
icantly induced proliferation in myofibroblasts at 48 h, the
signalling pathway inhibitory assays were also performed for
48 h. To investigate the role of the PI3K signalling pathway in
HMGB1-stimulated myofibroblast proliferation, the PI3K in-
hibitor LY294002 (50 μmol/l) was used. This inhibitor
completely abolished HMGB1-stimulated myofibroblast pro-
liferation (Fig. 2). The results from the MTT proliferation
assays suggested that LY294002 at 50 μM was non-toxic to
myofibroblasts at 48 h (data not shown). Therefore, these data
Fig. 1 Recombinant high mobility group box1 (HMGB1) stimulates
proliferation of myofibroblasts at 96 h (1-100 ng/ml). All results of the
Neutral Red Uptake assays are expressed as the percentage proliferation
compared to the control (0 ng/ml). Error bars represent SEM; n = 29,
***P< 0.001 compared with the control
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indicated that HMGB1-stimulated myofibroblast proliferation
was also mediated through activation of the PI3K signalling
pathway.
To investigate the role of the MAPK signalling pathway in
HMGB1-stimulated myofibroblast migration, the inhibitor of
p42/44 kinase, MAPK kinase (U0126, 10 μmol/l) was used.
This inhibitor completely inhibited HMGB1-stimulated
myofibroblast proliferation (Fig. 2). The results from the
MTT proliferation assays suggested that U0126 at 10 μM
was non-toxic to myofibroblasts at 48 h (data not shown).
Therefore, these data indicated that HMGB1-stimulated
myofibroblast proliferation was mediated through the activa-
tion of the MAPK signalling pathway.
Glucose deprivation triggers release of HMGB1 from can-
cer cells The release of HMGB1 under normoxic and anoxic
conditions and also in the absence or presence of glucose was
compared. Surprisingly, the amount of HMGB1 released from
cancer cells under normoxic conditions without glucose was
higher than those values under anoxic conditions with or with-
out glucose (anoxic data not shown). The increased release of
HMGB1 under low glucose conditions was detected in the
medium from HT-29 cells at both 24 h and 48 h in the pres-
ence of oxygen in HT-29 cells (Fig. 3a). In addition, we found
that this increase in HMGB1 release in the absence of glucose
did not occur under conditions in which the cells were
deprived of glutamine (Fig. 3c). This further confirmed that
glucose deprivation in the presence of oxygen was a strong
stimulant for HT-29 colon cancer cells to release HMGB1.
Release of HMGB1 in response to glucose deprivation is
not cancer-cell-line-specific The results from western blot
data showed that glucose deprivation triggered the release of
HMGB1 from HT-29 colon cancer cells (Fig. 3a). To investi-
gate whether this HMGB1 release was cell-line-specific or a
phenomenon shared by other cell lines, MCF-7 (breast can-
cer), EJ138 (bladder cancer) and A549 (lung cancer) cells
were also subjected to glucose deprivation. The culture medi-
um was again collected after 48 h and any HMGB1 released
Fig. 2 Recombinant HMGB1 stimulated myofibroblast proliferation
(48 h) in the presence of mitogen-activated protein kinase (MAPK) and
phosphatidylinositol 3-kinase (PI3K) inhibitors. The MEK1/2 inhibitor
U0126 (50 μM) and the PI3K inhibitor LY294002 (10 μM) significantly
inhibited HMGB1 (10 ng/ml)-stimulated myofibroblast proliferation.
Error bars represent SEM; n= 18, **P< 0.01
Fig. 3 Western blot analysis of conditioned medium demonstrated an
increase in HMGB1 in (a) HT-29 cells cultured in medium without glu-
cose for 24 h and 48 h compared with medium containing glucose and in
(b) MCF-7 and A549 cells cultured in medium without glucose for 48 h
compared with medium containing glucose. However, no change was
seen in the conditioned medium taken from EJ138 cells cultured in the
same way. c No change in the amount of HMGB1 was detected in medi-
um taken from HT-29 cells that had been cultured in medium from which
glutamine was absent compared with medium that contained glutamine at
48 h. All cells were exposed to normoxic conditions. Each western blot
was repeated a minimum of three times on three separate occasions
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into the medium was detected by western blot analysis
(Fig. 3b). The results suggested that, like the response of the
HT-29 colon cancer cell line, glucose deprivation also trig-
gered the release of HMGB1 from MCF-7 and A549 cells.
However, there appeared to be no difference in the level of
HMGB1 released from EJ138 cells cultured with or without
glucose. The MCF-7 and A549 cells followed the same pattern
with an increased amount of HMGB1 released under glucose-
deprived conditions compared with normal levels of glucose.
The MCF-7 cells showed the greatest difference in the quantity
of HMGB1 released, showing no detectable band in the
glucose-containing medium and a strong band in medium de-
prived of glucose after 48 h (Fig. 3b). Therefore, three out of the
four cell lines investigated appeared to follow the same pattern,
releasing relatively higher amounts of HMGB1 after glucose
deprivation under normoxic conditions (Fig. 3a, b).
Glucose-free medium conditioned by HT-29 colon adeno-
carcinoma cells triggers migration and invasion of
myofibroblastsMigration and invasion assays were performed
by using glucose-free conditionedmedium collected fromHT-29
colon cancer cells as a potential chemoattractant. This condi-
tioned medium served as a positive control (100 % migration
or 100% invasion) and was compared with conditionedmedium
with glucose and fresh medium with or without glucose. The
results obtained from these assays suggested that HT-29 cells
undergoing glucose starvation released chemoattractants that
stimulated the migration and invasion of myofibroblasts
(Figs. 4, 5). Glucose-containing conditioned medium also stim-
ulated the migration and invasion of myofibroblasts compared
with fresh medium but this was significantly lower than that
caused by glucose-free conditioned medium (Figs. 4, 5). These
data suggested that conditioned medium from HT-29 cells, espe-
cially glucose-depleted conditioned medium, significantly stim-
ulated the migration and invasion of myofibroblasts.
HMGB1 released from HT-29 colon adenocarcinoma cells
triggers invasion and migration in myofibroblasts
Increased HMGB1 in the conditioned medium was detected
from glucose-deprived HT-29 cell lines (Fig. 3a). To investi-
gate whether the HMGB1 present in this culture medium was
stimulating migration and invasion of myofibroblasts (Figs. 4,
5), migration and invasion assays were performed with the
addition of immunoneutralising anti-HMGB1 antibodies
(5 μg/ml) added to the glucose-free conditioned medium.
The addition of the anti-HMGB1 antibodies significantly
inhibited myofibroblast migration and invasion stimulated
by this glucose-free conditioned medium (Figs. 6a, 7a) sug-
gesting that HMGB1 plays an important role in the invasion
and migration of these cells in glucose deprivation.
HMGB1 binding to RAGE and TLR4 triggers invasion
and migration of myofibroblasts Although RAGE is the
main receptor for HMGB1, HMGB1 is known to interact with
other receptors including TLR4. Western blot analysis con-
firmed the presence of TLR4 and RAGE onmyofibroblast cells
(data not shown). Therefore, HMGB1-mediated migration and
invasion of myofibroblasts might involve the activation of an
HMGB1-RAGE complex and/or HMGB1-TLR4 complex,
resulting in the stimulation of downstream signalling cascades.
To investigate the role of these receptors in myofibroblast mi-
gration and invasion, myofibroblasts were stimulated with
glucose-free conditioned medium from HT-29 cells, with or
without the addition of immunoneutralising anti-RAGE anti-
bodies (8 μg/ml) or anti-TLR4 antibodies (2 μg/ml). The pres-
ence of either anti-RAGE antibodies or anti-TLR4 antibodies
significantly inhibited myofibroblast migration and invasion
stimulated by glucose-free HT-29-cell-conditioned medium
(Figs. 6a, 7a). These results suggested that the HMGB1 present
in the glucose-free conditioned medium from HT-29 cells stim-
ulated myofibroblast migration and invasion through the acti-
vation of both RAGE and TLR4.
HMGB1-tr iggered migrat ion and invas ion in
myofibroblasts involve activation of the MAPK and PI3K
Fig. 4 Conditioned medium (Cond. medium) from HT-29 cells cultured
in medium without glucose stimulated migration of myofibroblasts. The
migration assay was carried out with Boyden chamber inserts and the
cells were stimulated for 20 h. The myofibroblasts were exposed to
conditioned medium from HT-29 cells that either contained glucose or
lacked glucose and to fresh medium that also either contained glucose or
lacked glucose. All conditions were compared with conditioned medium
lacking glucose, which was expressed as 100 %. Error bars represent
SEM; ***P < 0.001; n = 3 for all conditions, except for conditioned
medium minus glucose where n= 7
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signalling pathways To investigate the possible downstream
signalling pathways involved in the migration and invasion of
myofibroblasts stimulated with glucose-free HT-29-cell-
conditioned medium, the potential roles of the MAPK and
PI3K signalling pathways were considered. Migration and
invasion assays were therefore carried out by using the selec-
tive inhibitors of MEK1/2 and PI3K. These inhibitors were
added to both the medium in the bottom chamber and to the
myofibroblast cell suspension in the inserts. The selective
MEK1/2 inhibitor U0126 (50 μM) significantly reduced
myofibroblast migration (Fig. 6b) and invasion (Fig. 7b) com-
pared with glucose-free conditioned medium. In addition,
LY294002 (10 μM), a selective inhibitor of PI3K, resulted
in a significant reduction in myofibroblast migration
(Fig. 6b) and invasion (Fig. 7b) compared with glucose-free
conditioned medium. These results suggested that both the
MAPK and PI3Kwere involved in the migration and invasion
of myofibroblasts stimulated by glucose-free HT-29-cell-
conditioned medium.
Discussion
In many solid tumours, including those of the colon and
breast, the tumour stroma comprises a major part of the
Fig. 5 Conditioned medium (Cond. medium) from HT-29 cells cultured
in medium without glucose stimulated invasion of myofibroblasts into a
Matrigel matrix. The myofibroblasts were exposed to conditioned
medium from HT-29 cells that either contained glucose or lacked glucose
and to fresh medium that did not contain glucose for 22 h. All conditions
were compared with conditioned medium lacking glucose, which was
expressed as 100 %. Error bars represent SEM; ***P< 0.001, n= 5
Fig. 6 Myofibroblast migration stimulated by glucose-free conditioned
medium from HT-29 cells was significantly inhibited by (a)
immunoneutralising antibodies to high mobility group box1 (HMGB1),
receptor for advanced glycation end products (RAGE) and toll-like
receptor 4 (TLR4) and (b) by the MEK1/2 inhibitor UO126 (50 μmol/l)
and the PI3K inhibitor LY294002 (10μmol/l).Error bars represent SEM;
**P <0.01, ***P< 0.001, n = 3 for all conditions, except for conditioned
medium minus glucose where n= 7
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tumour mass (Peña et al. 2013; Tripathi et al. 2012).
Myofibroblasts are the predominant stromal cell type in most
carcinomas and have been shown to take part in tumour pro-
liferation by secreting a number of growth factors, including
IGF-1, IGF-II and HGF (Hinz et al. 2007; Tripathi et al. 2012).
However, the role of cancer cells in the stimulation of
myofibroblasts has not been fully explored. The proliferative
and migratory properties of HMGB1, a novel non-histone
nuclear protein, have been an area of recent interest and
HMGB1 has been reported to be involved in the proliferation
of fibroblasts from the lung (Li et al. 2015) and in the prolif-
eration and migration of fibroblasts from gingival and peri-
odontal tissue (Chitanuwat et al. 2013), in keratinocytes
(Ranzato et al. 2009) and in skin fibrobroblasts (Ranzato
et al. 2010). Limited evidence of the role of HMGB1 in the
stimulation of myofibroblast migration is available (Lee et al.
2015) but no evidence exists to date regarding the role of
HMGB1 in stimulating other activities of myofibroblasts,
such as proliferation and invasion. The data presented here
show that recombinant HMGB1 at 10 ng/ml significantly
stimulates myofibroblast proliferation. Furthermore, our re-
sults suggest that HMGB1 is actively released by cancer cells
under stressful conditions and that this might regulate the pro-
liferation, migration and invasion of myofibroblasts.
Together with hypoxia, glucose deprivation has been con-
sidered to be a major hallmark of the solid tumour microenvi-
ronment (Jang and Hill 1997). The results of our work show
that the nuclear protein HMGB1 is released from glucose-
deprived cancer cells. The presence of HMGB1 in the culture
medium of macrophages and monocytes has been reported pre-
viously (Tang et al. 2007). Cells undergoing autophagy are
thought to release HMGB1 into the microenvironment
(Thorburn et al. 2009a). Autophagy has been shown to be in-
duced by nutrient starvation (L. Li et al. 2013). However,
whether the deprivation of a particular nutrient is responsible
for the release of HMGB1 into the microenvironment during
autophagy is unclear. Nevertheless, our western blot data sug-
gest that glucose deprivation triggers the release of HMGB1
from HT-29 cells under normoxic conditions. HMGB1 is also
released from HT-29 cells under anoxic conditions (data not
shown). Anoxic conditions cause oxidative stress to cells and
therefore they might be stimulated to undergo autophagy (Yang
et al. 2015). Autophagic cells have previously been shown to
selectively release HMGB1 without disrupting the cell mem-
brane via an unknownmechanism (Thorburn et al. 2009b). The
amount of HMGB1 released under glucose-deprived normoxic
conditions is much higher than other conditions investigated.
These include anoxia in addition to glucose deprivation (data
not shown), a much harsher microenvironmental condition.
This suggests that the release of HMGB1 from HT-29 cells is
not the result of autophagy but is potentially induced by a
specific microenvironmental stress (glucose deprivation) stim-
ulating active secretion. The release of HMGB1 from glucose-
Fig. 7 Myofibroblast invasion into a Matrigel matrix stimulated by
glucose-free conditioned medium from HT-29 cells was significantly
inhibited by (a) immunoneutralising antibodies to HMGB1, RAGE and
TLR4 and (b) by the MEK1/2 inhibitor UO126 (50 μM) and the PI3K
inhibitor LY294002 (10 μM). Error bars represent SEM; **P < 0.01,
***P< 0.001, n= 5
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deprived HT-29 cells might be nutrient-specific, as glutamine
deprivation does not have the same effect. Additionally, other
cell lines have been investigated to determine whether the re-
lease of HMGB1 under conditions of glucose deprivation is
cell-line-specific. Our western blot results suggest that glucose
deprivation in normoxic conditions also stimulates the release
of HMGB1 from cancer cell lines MCF-7 (breast) and A549
(lung), but not from EJ138 bladder cancer cells.
The data from the migration and invasion assays indicate
that HMGB1 present in low-glucose culture medium taken
from HT-29 cells triggers the migration and invasion of
myofibroblasts. The involvement of HMGB1 in this migration
and invasion has been confirmed by using immunoneutralising
antibodies against HMGB1, whereby the presence of anti-
HMGB1 antibodies results in a statistically significant reduc-
tion in the migration and invasion of myofibroblasts. This sug-
gests a key role of HMGB1 in the regulation of these processes.
HMGB1 has been shown to interact with many receptors in-
cluding TLR4 and RAGE. For example, the interaction of
HMGB1 with TLR4 has been implicated in stimulating the
proliferation and migration of hepatic stellate cells via the acti-
vation of the PI3K pathway (Wang et al. 2013). Moreover, the
activity of the HMGB1-RAGE complex has been implicated in
the regulation of the migration of dendritic cells and myoblasts
(Dumitriu et al. 2007; Riuzzi et al. 2006). Results from western
blot analysis have revealed that TLR4 and RAGE are expressed
bymyofibroblasts (data not shown). In this study, we report that
the inhibition of TLR4 or RAGE by immunoneutralising anti-
bodies statistically significantly inhibits the migration and inva-
sion of myofibroblasts. This suggests that an interaction be-
tween HMGB1 and either of these receptors mediates the acti-
vation of downstream signalling pathways to trigger migration
and invasion. HMGB1 might also interact with other receptors,
which are as yet to be investigated.
The activation of the PI3K and MAPK pathways in both
the proliferation and migration of cancer cells, inflammatory
cells and myofibroblasts has been previously reported
(Hemers et al. 2005; Kang et al. 2013; Mahajan and
Dhawan 2013). In addition, both pathways have been previ-
ously shown to be involved in the invasion of hepatocellular
carcinoma and prostate cancer cells (Chen et al. 2005).
However, an involvement of these pathways in HMGB1-
stimulated myofibroblast proliferation, migration and inva-
sion has not previously been reported. To determine the in-
volvement of the signalling pathways in HMGB1-stimulated
proliferation, migration and invasion, PI3K andMEK1/2 have
been selectively inhibited by using U0126 and LY294002,
respectively. The results suggest that HMGB1-induced prolif-
eration, migration and invasion of myofibroblasts involves the
activation of the PI3K and MAPK signalling pathways.
The results from this work have shown that HMGB1, a
histone-associated nuclear protein normally involved in
DNA stabilisation, is actively released from cancer cells in
response to low-glucose levels. Cancer cells, under certain
microenvironmental stress conditions, such as hypoxia or
low glucose, are known to become more aggressive and inva-
sive and also more likely to metastasise (Evans et al. 2008).
Our study has shown that HMGB1 interacts with TLR4 and
RAGE expressed by myofibroblasts. The TLR4 or RAGE
interaction with HMGB1 released from cancer cells engages
downstream the PI3K and MAPK pathways to signal the
myofibroblasts to proliferate, migrate and invade. The release
of HMGB1 from cancer cells under low-glucose conditions
and its subsequent interaction with myofibroblasts have not
been previously reported. These findingsmight have profound
implications for our understanding of the carcinogenesis pro-
cess and therefore may reveal novel therapeutic targets for the
treatment of cancer.
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